International Heart Valve Bank Survey: A Review of Processing Practices and Activity Outcomes

Table 9

Summary table of heart valve outcomes for HVBs in Australasia and South Africa.

Bank	Number of donors/number of grafts processed annually (average)	Proportion of products meeting release criteria	Reasons for product failure	Proportion of released products implanted	Reasons released products are not implanted
A1	12 donors; 16 valves	~75%	(1) Positive microbiological results of graft; (2) Abnormal morphology of graft	77%	(1) Size demand for aortic valves; (2) Low demand for aortic valves
A2	27 donors; 77 grafts	~50%	(1) Positive microbiological results of graft; (2) Donor related (medical contradiction)	90–100%	Size demand for aortic valves
A3	80 donors; 232 grafts; (118 valves and 114 patches)	~70%	(1) Positive microbiological results of graft; (2) Positive serology results of donor	100% for pulmonary valves; majority for aortic valves; 100% for patches	(1) Size demand for aortic valves; (2) Beyond maximum storage duration
A4	20 donors; 36 valves	~83%	(1) Positive microbiological results of graft; (2) Abnormal morphology	74%	Low demand for aortic valves
A5	24 donors; 34 valves	90%	Positive microbiological results of graft	~100%	(1) Quality of graft; (2) Beyond maximum storage duration
A6	29 donors; 49 valves	~71%	(1) Positive microbiological results of graft; (2) Abnormal morphology; (3) Failure in valve competency	91%	Nonvalve grafts are not in demand
A7	75 donors; 98 valves	~61%	(1) Positive serology results of donor; (2) Positive microbiological results of graft; (3) Abnormal morphology of graft	~80%	Size demand for valves